Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Hadassah Medical Organization |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00310882 |
The endogenous digitalis-like compounds (DLC)are steroid hormones synthesized and released from the adrenal gland.They are integrated in the feed-back system of the Hypothalami-Pituitary-Adrenal gland axis.One of their remarkable function is to induce apoptosis in malignant cells. Recently, accumulating data point to the possibility of using synthetic DLC as new anti-cancer drugs. Less is known about the endogenous metabolism of these compounds in cancer patients. Proceeding from preliminary clinical data which demonstrated significantly reduced DLC plasma levels in breast cancer patients and from in vitro data which showed an impaired release of DLC towards stress stimuli in athymic nude mice,we put up the hypothesis that a latent adrenal insufficiency with low DLC levels facilitates the induction and progression of tumor diseases.
Condition |
---|
Breast Neoplasms Fibrocystic Disease of Breast Mammaplasty |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Involvement of Endogenous Digitalis-Like Compounds in Breast Cancer |
blood samples
Estimated Enrollment: | 250 |
Study Start Date: | May 2006 |
Estimated Study Completion Date: | May 2008 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Women with first diagnosis of Breast Cancer or a benign Breast Disease
Inclusion Criteria:
Exclusion Criteria:
Contact: Heidrun Weideman, MD | +972-50-8946378 | hweidemann@freenet.de |
Contact: Tanir Allweis, MD | +972-50-787-4268 | tanir@hadassah.org.il |
Israel | |
Hadassah Hebrew University Medical Centers | Recruiting |
Jerusalem, Israel | |
Principal Investigator: Heidrun Weidemann, MD | |
Sub-Investigator: Tanir M Allweis, MD | |
Sub-Investigator: Asher Salmon, MD |
Principal Investigator: | Heidrun Weideman | Hadassah Hebrew University Medical Centers |
Responsible Party: | Hadassah Medical Organization ( Dr. Tanir Allweiss ) |
Study ID Numbers: | 297-31.3-06-HMO-CTIL |
Study First Received: | April 4, 2006 |
Last Updated: | May 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00310882 History of Changes |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
breast cancer digitalis like compounds prognostic factor |
Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Skin Diseases Fibrocystic Breast Disease Cystic Fibrosis |
Fibrosis Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases Breast Neoplasms Breast Diseases |
Fibrocystic Breast Disease Skin Diseases Breast Neoplasms Neoplasms Neoplasms by Site Digestive System Diseases Cystic Fibrosis |
Respiratory Tract Diseases Genetic Diseases, Inborn Lung Diseases Pancreatic Diseases Infant, Newborn, Diseases Breast Diseases |